Oncology Corporate Profile
Genentech has been delivering on the promise of biotechnology for more than 30 years, using human genetic information to discover, develop, manufacture and commercialize biotherapeutics that address significant unmet medical needs. Today, Genentech is among the world's leading biotech companies, with multiple products on the market and a promising development pipeline. In March 2009, Genentech became a wholly owned member of the Roche Group.
|Alecensa®||alectinib||Alecensa® is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK) - positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response.|
|Avastin®||bevacizumab||Avastin® is a vascular endothelial growth factor-specific angiogenesis inhibitor indicated for the treatment of:|
• Metastatic colorectal cancer, with intravenous 5-fluorouracil'based chemotherapy for first- or second-line treatment.
• Non-squamous non-small cell lung cancer, with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease.
• Metastatic breast cancer, with paclitaxel for treatment of patients who have not received chemotherapy for metastatic HER2-negative breast cancer.
• Effectiveness based on improvement in progression-free survival. No data available demonstrating improvement in disease-related symptoms or survival with Avastin.
• Not indicated for disease progression following anthracycline and taxane chemotherapy administered for metastatic disease.
• Glioblastoma, as a single agent for patients with progressive disease following prior therapy.
• Effectiveness based on improvement in objective response rate. No data available demonstrating improvement in disease-related symptoms or survival with Avastin.
• Metastatic renal cell carcinoma with interferon alfa.
• In combination with chemotherapy for the treatment of women with platinum-resistant, recurrent ovarian cancer.
|Cotellic®||Cobimetinib||Cotellic® is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.|
|Erivedge®||vismodegib||Erivedge® (vismodegib) capsule is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.|
|Gazyva®||obinutuzumab||Gazyva® (obinutuzumab) is a CD20-directed cytolytic antibody and is indicated in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia; in combination with bendamustine followed by GAZYVA monotherapy, for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen; in combination with chemotherapy followed by Gazyva® monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma|
|Herceptin®||trastuzumab||Adjuvant Breast Cancer|
Herceptin® is indicated for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature breast cancer
• as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
• with docetaxel and carboplatin
• as a single agent following multi-modality anthracycline based therapy.
Metastatic Breast Cancer
Herceptin® is indicated:
• In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer
• As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease.
|Kadcyla®||ado-trastuzumab emtansine||Kadcyla® is a HER2 targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.|
|Kytril®||granisetron HCL||Kytril® (granisetron HCL) is indicated for the prevention of nausea and vomitting associated with initial and repeat courses of emetogenic cancer therapy, including high does cisplatin. Nausea and vomitting associated with radiation, including total body irradiation and fractionated abdominal radiation.|
|Perjeta®||pertuzumab||Perjeta® (pertuzumab) is a HER2/neu receptor antagonist indicated in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.|
|Rituxan Hycela™||rituximab and hyaluronidase human||Rituxan Hycela™ is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with: -Follicular Lymphoma (FL); relapsed or refractory, follicular lymphoma as a single agent; previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as singleagent maintenance therapy; non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. -Diffuse Large B-cell Lymphoma (DLBCL); previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens. And Chronic Lymphocytic Leukemia (CLL); previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide (FC)|
|Rituxan®||rituximab||Non-Hodgkin's Lymphoma (NHL)|
Rituxan® (rituximab) is indicated for the treatment of patients with:
• Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
• Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
• Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy
• Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
Chronic Lymphocytic Leukemia (CLL)
Rituxan® (rituximab) is indicated, in combination with fludarabine and cyclophosphamide (FC), for the treatment of patients with previously untreated and previously treated CD20-positive CLL.
|Roferon-A®||Interferon alfa-2a, recombinant||Roferon-A® is indicated for the treatment of chronic hepatitis C and hairy cell leukemia in patients 18 years of age or older. In addition, it is indicated for chronic phase Philadelphia chromosome (PH) positive chronic myelogenous leukemia (CML) patients who are minimally pretreated (within 1 year of diagnosis).|
|Tarceva®||erlotinib||Tarceva® is a kinase inhibitor indicated for:|
• Maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy
• Treatment of locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
• First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.
|Tecentriq®||atezolizumab||Tecentriq® is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of patients with:|
• Locally advanced or metastatic urothelial carcinoma who:
• are not eligible for cisplatin-containing chemotherapy, or
• have disease progression during or following any platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant
chemotherapy. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
• Metastatic non-small cell lung cancer who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA approved therapy for these aberrations prior to receiving Tecentriq®.
|Vesanoid®||tretinoin||Vesanoid® (tretinoin) capsules are indicated for the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant), characterized by the presence of the t(15;17) translocation and/or the presence of the PML/RARalpha gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline-based chemotherapy is contraindicated. VESANOID is for the induction of remission only. The optimal consolidation or maintenance regimens have not been defined, but all patients should receive an accepted form of remission consolidation and/or maintenance therapy for APL after completion of induction therapy with VESANOID.|
* Xeloda® is indicated as a single agent for adjuvant treatment in patients with Dukes' C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. Xeloda® was non-inferior to 5-fluorouracil and leucovorin (5-FU/LV) for disease-free survival (DFS). Although neither Xeloda® nor combination chemotherapy prolongs overall survival (OS), combination chemotherapy has been demonstrated to improve disease-free survival compared to 5-FU/LV. Physicians should consider these results when prescribing single-agent Xeloda® in the adjuvant treatment of Dukes' C colon cancer.
* Xeloda® is indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. Combination chemotherapy has shown a survival benefit compared to 5-FU/LV alone. A survival benefit over 5-FU/LV has not been demonstrated with Xeloda® monotherapy. Use of Xeloda® instead of 5-FU/LV in combinations has not been adequately studied to assure safety or preservation of the survival advantage.
* Xeloda® in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.
* Xeloda® monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated, eg, patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents. Resistance is defined as progressive disease while on treatment, with or without an initial response, or relapse within 6 months of completing treatment with an anthracycline-containing adjuvant regimen.
|Zelboraf®||vemurafenib||Zelboraf® is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. Zelboraf® is also indicated for the treatment of patients with ErdheimChester Disease with BRAF V600 mutation.|
View additional information on commercial products here »
|Brand / Product||Class||Area of Study||Phase||Partnership|
|trastuzumab emtansine||antibody drug conjugate||1st line metastatic Breast cancer (HER2+)||III|
|trastuzumab emtansine||antibody drug conjugate||3rd line metastatic Breast cancer (HER2+)||III|
|obinutuzumab / GA101||anti-CD20 monoclonal antibody||Diffuse large B-cell Lymphoma (DLBCL)||III|
|obinutuzumab / GA101||anti-CD20 monoclonal antibody||Front-line chronic lymphocytic leukemia||III|
|obinutuzumab / GA101||anti-CD20 monoclonal antibody||Front-line indolent non-Hodgkin's lymphoma||III|
|cobimetinib / GDC-0973||selective MEK inhibitor||Melanoma||III|
|obinutuzumab / GA101||anti-CD20 monoclonal antibody||Refractory indolent Non Hodgkin's lymphoma||III|
|Alecensa® / alectinib||selective ALK (anaplastic lymphoma kinase) inhibitor||ALK-positive Non Small Cell Lung Cancer (NSCLC)||III|
|Avastin® / bevacizumab||anti-VEGF monoclonal antibody||1st line metastatic Ovarian cancer||III|
|Avastin® / bevacizumab||anti-VEGF monoclonal antibody||Adjuvant Breast cancer (HER2+)||III|
|Avastin® / bevacizumab||anti-VEGF monoclonal antibody||Adjuvant Breast cancer (HER2-)||III|
|Avastin® / bevacizumab||anti-VEGF monoclonal antibody||Glioblastoma Multiforme (GBM)||III|
|Avastin® / bevacizumab||anti-VEGF monoclonal antibody||Non Small Cell Lung Cancer (NSCLC)||III|
|Avastin® / bevacizumab||anti-VEGF monoclonal antibody||Various cancer types||III|
|Perjeta® / pertuzumab||monoclonal antibody||Early Breast cancer (HER2+)||III|
|Tarceva® / erlotinib||EGFR inhibitor||1st line metastatic Non Small Cell Lung Cancer (NSCLC)||III|
|Zelboraf® / vemurafenib||BRAF kinase inhibitor||Melanoma||III|
|GDC-0810||selective estrogen receptor degrader (SERD)||Breast cancer (HER2-)||II|
|polatuzumab vedotin||antibody drug conjugate||Diffuse large B-cell Lymphoma (DLBCL)||II|
|ipatasertib / GDC-0068||pan-Akt inhibitor||Gastric cancer||II|
|polatuzumab vedotin||antibody drug conjugate||Non-Hodgkin's Lymphoma (NHL)||II|
|ipatasertib / GDC-0068||pan-Akt inhibitor||Prostate cancer||II|
|ipatasertib / GDC-0068||pan-Akt inhibitor||Triple negative Breast cancer||II|
|Erivedge® / vismodegib||hedgehog pathway inhibitor||Basal Cell Carcinoma (BCC)||II|
|Perjeta® / pertuzumab||monoclonal antibody||2nd line metastatic Breast cancer (HER2+)||II|
|Perjeta® / pertuzumab||monoclonal antibody||Gastric cancer||II|
|Zelboraf® / vemurafenib||BRAF kinase inhibitor||Thyroid cancer||II|
|taselisib / GDC-0032||PI3K Inhibitor||Breast cancer (HER2+)||I|
|GDC-0927||selective estrogen receptor degrader (SERD)||Breast cancer (HER2-)||I|
|GDC-0077||PI3K Inhibitor||Breast cancer (HER2-)||I|
|taselisib / GDC-0032||PI3K Inhibitor||Breast cancer (HER2-)||I|
|venetoclax / GDC-0199||Bcl-2 selective inhibitor||Chronic Lymphocytic Leukemia (CLL)||I|
|atezolizumab||monoclonal antibody targeting PD-L1||Melanoma||I|
|unknown||antibody drug conjugate||Non-Hodgkin's Lymphoma (NHL)||I|
|venetoclax / GDC-0199||Bcl-2 selective inhibitor||Non-Hodgkin's Lymphoma (NHL)||I|
|unknown||antibody drug conjugate||Ovarian cancer||I|
|unknown||antibody drug conjugate||Pancreatic cancer||I|
|anti-TIGIT||monoclonal antibody||Various cancer types||I|
|anti-OX40||monoclonal antibody||Various cancer types||I|
|atezolizumab||monoclonal antibody targeting PD-L1||Various cancer types||I|
|ipatasertib / GDC-0068||pan-Akt inhibitor||Various cancer types||I|
|GDC-0919||IDO inhibitor||Various cancer types||I|
|cobimetinib / GDC-0973||selective MEK inhibitor||Various cancer types||I|
|GDC-0575||CHK1 inhibitor||Various cancer types||I|
|GDC-0077||PI3K Inhibitor||Various cancer types||I|
|taselisib / GDC-0032||PI3K Inhibitor||Various cancer types||I|
|Zelboraf® / vemurafenib||BRAF kinase inhibitor||Metastatic Melanoma||I|
View additional information on product candidates here »
11/7/2016 12:56 pm
(Yahoo! Finance) Nov 7, 2016 - Encouraging data in BRAF wild type advanced melanoma presented in advance of initiation of phase 3 pivotal trial next year; the third pivotal phase 3 trial of cobimetinib announced this year, reflecting robust late-stage development program.
11/4/2016 04:03 pm
(AACR) Nov 3, 2016 - Stand Up To Cancer (SU2C) announced today an SU2C Catalyst™ collaboration with Genentech, a member of the Roche Group, that will help accelerate the development of new cancer treatments and combination therapies by giving awardees funding and access to a dozen of the company's medicines.
10/31/2016 03:33 pm
(MarketWatch) Oct 30, 2016 - Licensing of GDC-0084, a small molecule phosphoinositide-3-kinase (PI3K) inhibitor developed by Genentech, is ready to enter a phase II clinical trial in glioblastoma multiforme (GBM).
10/18/2016 08:52 pm
(Genentech) Oct 18, 2016 - First and only anti-PDL1 cancer immunotherapy approved by the FDA for metastatic non-small cell lung cancer (NSCLC); approval based on survival benefit of TECENTRIQ compared to docetaxel chemotherapy, regardless of PD-L1 status.
10/7/2016 03:58 pm
(Yahoo! Finance) Oct 7, 2016 - Exelixis, Inc. today announced that its collaborator Genentech, a member of the Roche Group, will present preliminary results from a phase 1b clinical trial evaluating the safety and clinical activity of the triple combination of cobimetinib, vemurafenib, and atezolizumab in patients with previously untreated BRAF V600 mutation-positive advanced melanoma.
10/4/2016 12:18 pm
(StreetInsider) Oct 4, 2016 - This second Alecensa Breakthrough Therapy Designation was granted based on Phase III J-ALEX study.
9/29/2016 05:30 pm
(GEN) Sept 29, 2016 - Genentech, a member of the Roche Group, will develop and commercialize Hanmi Pharmaceutical’s Phase I cancer candidate HM95573 in most of the world, through a license agreement that could generate up to $910 million for the South Korean drug developer.
9/21/2016 05:08 pm
(San Francisco Business Times/BiotechSF) Sept 21, 2016 - Genentech Inc. will shell out an initial $310 million in a partnership with Germany's BioNTech to develop personalized cancer vaccines, the company said late Tuesday.
7/18/2016 11:50 am
(Morningstar) July 18, 2016 - GOYA study did not meet its primary endpoint of improvement in progression-free survival with Gazyva plus CHOP chemotherapy versus Rituxan plus CHOP chemotherapy.
6/28/2016 12:02 pm
(IASLC) June 28, 2016 - The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) announced today the open comment period for the revised evidence-based guideline, "Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors.”
6/28/2016 12:01 pm
(New York Times/Well blog) June 28, 2016 - Now an influential government task force says there isn’t evidence that routine pelvic exams are necessary or prolong a woman’s life. Some experts think they may even do more harm than good.
6/27/2016 11:05 am
(UNM CCC) June 24, 2016 - Vice President Biden and Dr. Jill Biden will host a Cancer Moonshot Summit in Washington, D.C. at the White House. Cheryl Willman, MD, Director and CEO of The University of New Mexico Comprehensive Cancer Center, will attend. At the same time, the UNM Comprehensive Cancer Center will host a local Cancer Moonshot Summit.
6/27/2016 11:04 am
(STAT/Pharmalot) June 24, 2016 - In an unusual step, the pharmaceutical industry trade group in the United Kingdom has suspended Astellas for a year after discovering the drug maker disguised the true purpose of a meeting held for doctors, and then senior executives compounded the infraction by withholding crucial information when asked to explain the arrangements.
6/27/2016 11:04 am
(Medscape Medical News) June 24, 2016 - Testing core needle biopsy specimens of ductal carcinoma in situ (DCIS) for hormone receptors is wasteful because testing is better done after surgery.
6/20/2016 12:02 pm
(New Jersey Online) June 20, 2016 - Regional Cancer Care Associates LLC, or RCCA, is one of a select group of oncology organizations nationwide invited by the Centers for Medicare and Medicaid Services (CMS) to participate in the agency's Oncology Care Model, or OCM.
6/10/2016 11:00 am
(AACR) June 9, 2016 - American Association for Cancer Research (AACR) President Nancy E. Davidson, MD, moderated a special session for AACR leaders, including young and early-stage investigators and minority researchers, with members of the National Cancer Institute (NCI) Blue Ribbon Panel last week to help inform the NCI’s scientific direction and goals in Vice President Joe Biden’s National Cancer Moonshot Initiative.
6/10/2016 10:05 am
(GlycoMimetics) June 10, 2016 - GlycoMimetics, Inc. today announced data from the Phase 1 portion of its Phase 1/2 clinical trial of its novel E-selectin antagonist, GMI-1271, combined with induction chemotherapy, in patients with relapsed/refractory acute myeloid leukemia (AML). Dose escalation is complete and a GMI-1271 dose was identified for Phase 2 testing.
6/9/2016 11:03 am
(Reuters) June 8, 2016 - Sanofi said on Wednesday it aims to remove the board of takeover target Medivation by Aug. 1 at the latest.
6/9/2016 11:01 am
(UC Academic Health Center) June 9, 2016 - Researchers at the University of Cincinnati College of Medicine have found that putting liver cancer patients on a medication regimen prior to undergoing a certain treatment could lead to shorter hospital stays and less chance for readmission due to complications.
6/9/2016 11:01 am
(Basilea Pharmaceutica) June 9, 2016 - Basilea Pharmaceutica Ltd. announced today that the final clinical data from the first-in-human phase 1/2a study with the intravenous (i.v.) form of its tumor checkpoint controller BAL101553 were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, USA, on June 3-7, 2016.
6/9/2016 11:00 am
(Society of Thoracic Surgeons) June 9, 2016 - A single breath may be all it takes to identify the return of lung cancer after surgery, according to a study posted online today by The Annals of Thoracic Surgery.
6/9/2016 11:00 am
(UCLA) June 8, 2016 - UCLA researchers’ findings could offer a non-invasive and more cost-effective method to detect lung cancer.
6/6/2016 02:00 pm
(2016 ASCO Annual Meeting) June 6, 2016 - For breast cancer survivors who carry mutations in BRCA genes, preventive surgery can substantially reduce the risk of future breast and ovarian cancer.
6/5/2016 11:19 pm
(Yahoo! Finance) June 5, 2016 - Exelixis, Inc. today announced that its collaborator Genentech, a member of the Roche Group, will present preliminary results from a phase 1b clinical trial evaluating the safety and clinical activity of cobimetinib, an Exelixis-discovered MEK inhibitor, in combination with atezolizumab, an anti-PD-L1 antibody discovered and developed by Genentech, in patients with metastatic colorectal cancer (CRC).
6/5/2016 11:07 pm
(Genentech) June 5, 2016 - Genentech, a member of the Roche Group, today announced that in a Phase II study, IMvigor 210, TECENTRIQ™ (atezolizumab) shrank tumors (objective response rate, ORR) in 24 percent (n=28) of people with locally advanced or metastatic urothelial carcinoma (mUC) who have not received a prior treatment (first-line) and who were ineligible for cisplatin-based chemotherapy.
6/5/2016 06:00 pm
(2016 ASCO Annual Meeting) June 5, 2016 – A National Cancer Institute (NCI) funded phase III trial performed by the Children's Oncology Group found that adding a second autologous stem-cell transplant (ASCT, a transplant that uses the patient's own stem cells) to standard therapy improves outcomes for patients.
6/4/2016 05:05 pm
(Forbes) June 3, 2016 - Some states are attempting to pass laws to gain control over drug price increases. Vermont Governor Peter Shumlin has just signed into law a bill to do just that.
6/4/2016 05:02 pm
(Moffitt) June 4, 2016 - Patients with recurrent high-grade glioma brain tumors have few effective treatment options and the majority of available therapies do not improve survival. Moffitt Cancer Center will present preliminary results from a phase 1 study testing whether the addition of pembrolizumab to radiation therapy and bevacizumab is safe and can control tumor growth for these patients.
6/3/2016 02:00 pm
(ASCO Annual Meeting) June 3, 2016 - For some women with advanced ovarian cancer that was successfully treated surgically, delivering chemotherapy into the abdomen (intraperitoneal, or IP) as well as intravenously (IV) appears more effective than IV chemotherapy alone.
6/3/2016 01:01 pm
(MedPage Today) June 2, 2016 - In a 24-patient phase Ib study of advanced endometrial tumors with PD-L1 expression, the PD-1 inhibitor pembrolizumab resulted in three patients (13%) achieving stable disease (95% CI 2.8-33.6, median duration 24.6 weeks), and three patients having a partial response (95% CI 2.8-33.6).
6/2/2016 12:01 pm
(Wall Street Journal) June 1, 2016 - A high-level revolt is erupting among National Institutes of Health doctors who are disputing an outside panel’s assessment that an unsafe culture existed at the agency’s renowned hospital, and are protesting a shake-up of senior leadership based on the findings.
6/1/2016 12:00 pm
(Penn Medicine) June 1, 2016 - Nearly 20 percent of women with ovarian cancer do not undergo surgery, despite it being a standard part of treatment recommendations, according to new research from the Perelman School of Medicine at the University of Pennsylvania.
6/1/2016 11:05 am
(ASCO in Action) May 31, 2016 - As ASCO and other groups continue to urge The Centers for Medicare & Medicaid Services (CMS) to withdraw the agency's proposed Medicare Part B demonstration project, the controversy around the flawed experiment is making headlines around the country including in Diagnosis: Cancer--a new blog from the Philadelphia Inquirer and Philly.com--which recently posted an op-ed from ASCO President Julie M. Vose, MD, MBA, FASCO.
5/31/2016 12:00 pm
(New York Times/The Upshot blog) May 30, 2016 - For some of the most important drugs, the prices may be too low, giving rise to shortages.
5/31/2016 10:05 am
(MedPage Today) May 27, 2016 - The FDA approved the radioactive diagnostic agent fluciclovine (F-18, Axumin) for use with positron emission tomography (PET) to detect recurrent prostate cancer.
5/27/2016 11:51 am
(Genentech) May 26, 2016 - Phase III GALLIUM study met primary endpoint early, as determined by independent data monitoring committee.
5/23/2016 12:19 pm
(STAT/Pharmalot) May 20, 2016 - Yet another health care provider is accusing Genentech of fudging the amount of the Herceptin medicine that the company provides in each vial, causing the facility and many other hospitals to overpay for the pricey treatment.
5/23/2016 12:01 pm
(STAT/Pharmalot) May 19, 2016 - In less than a month, Vermont could become the first state in the country to require drug makers to justify price hikes on their medicines, a move that may prompt others to take similar action but also spark a battle with the pharmaceutical industry.